Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 6Active not recruiting 3Terminated 2Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 6Carcinoma, Renal Cell 5Brain Neoplasms 3Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Kidney Neoplasms 2Glioma 2Glioblastoma 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Thyroid cancer, medullary 1Thyroid Neoplasms 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Thrombocytosis 1Skin Neoplasms 1Salivary Gland Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Cyclophosphamide 9fludarabine 8Interleukin-2 8aldesleukin 7Sunitinib 6Everolimus 6Bevacizumab 6fludarabine phosphate 5Sorafenib 5Radiotherapy 4Nivolumab 4Gene Expression Profiling 4Filgrastim 4pembrolizumab 3peginterferon alfa-2b 3Stem Cell Transplantation 3Radiotherapy, Intensity-Modulated 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3cabozantinib 2atezolizumab 2Thiotepa 2Sodium Chloride 2Reverse Transcriptase Polymerase Chain Reaction 2Polymerase Chain Reaction 2Mycophenolic Acid 2Mesna 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Kidney Neoplasms × cabozantinib × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Nektar Therapeutics

Phase 3 Terminated
623 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡